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OBJECTIVE—Blockade of the CB1 receptor is one of the prom-
ising strategies for the treatment of obesity. Although antagonists
suppress food intake and reduce body weight, the role of central
versus peripheral CB1 activation on weight loss and related meta-
bolic parameters remains to be elucidated. We therefore specifically
assessed and compared the respective potential relevance of central
nervous system (CNS) versus peripheral CB1 receptors in the
regulation of energy homeostasis and lipid and glucose metabolism
in diet-induced obese (DIO) rats.
RESEARCH DESIGN AND METHODS—Both lean and DIO
rats were used for our experiments. The expression of key
enzymes involved in lipid metabolism was measured by real-time
PCR, and euglycemic-hyperinsulinemic clamps were used for
insulin sensitivity and glucose metabolism studies.
RESULTS—Specific CNS-CB1 blockade decreased body weight
and food intake but, independent of those effects, had no
beneficial influence on peripheral lipid and glucose metabolism.
Peripheral treatment with CB1 antagonist (Rimonabant) also
reduced food intake and body weight but, in addition, indepen-
dently triggered lipid mobilization pathways in white adipose
tissue and cellular glucose uptake. Insulin sensitivity and skeletal
muscle glucose uptake were enhanced, while hepatic glucose
production was decreased during peripheral infusion of the CB1
antagonist. However, these effects depended on the antagonist-
elicited reduction of food intake.
CONCLUSIONS—Several relevant metabolic processes appear
to independently benefit from peripheral blockade of CB1, while
CNS-CB1 blockade alone predominantly affects food intake and
body weight. Diabetes 57:2977–2991, 2008
The incidence of obesity and the metabolic syn-drome have grown to epidemic proportions,making increased research efforts toward dis-covery of novel anti-obesity therapies increas-
ingly important. Endocannabinoids are key modulators of
feeding behavior through the activation of the CB1 recep-
tor (1,2), which is localized in the periphery as well as in
many brain areas involved in the regulation of energy
homeostasis and reward processes (3,4). Recent studies
(5–11) have demonstrated that blocking the activity of the
endogenous cannabinoid system may be a successful
strategy for the treatment of obesity and the metabolic
syndrome.
It is well known that CB1 receptors in the hypothalamus
might regulate food intake through the disinhibition of the
release of melanin-concentrating hormone from lateral
hypothalamic neurons (12) and the inhibition of the re-
lease and/or expression of corticotrophin-releasing hor-
mone in the paraventricular nucleus (13). Both these
effects are under the negative control of leptin, which is
known to negatively control endocannabinoid tone in the
hypothalamus (2). On the other hand, the effects of CB1
activation on -melanocyte–stimulating hormone are con-
troversial, since both inhibition and stimulation were
reported in the study by Hentges et al. (14), and no
downstream effects of -melanocyte–stimulating hormone
on endocannabinoid levels were found in the hypothala-
mus (15).
There is compelling evidence that beneficial effects of
CB1 blockade on metabolism may exceed the anorexi-
genic response (16–18). For instance, the treatment with
the CB1 antagonist SR141716 caused only a transient
suppression in food intake but a maintained reduction in
body weight in diet-induced obese (DIO) mice (19) and
Zucker rats (20). Those findings were consistent with
other observations suggesting that the blockade of CB1
increases energy expenditure (21). These pharmacological
data have been supported by data from genetic models.
CB1 receptor knockout mice have significantly less fat
mass than wild-type animals and are resistant to diet-
induced obesity, even though their caloric intake is similar
to that of wild-type animals (22,23). Collectively, these
results suggest that changes in food intake are not critical
and imply that endocannabinoids may regulate peripheral
metabolism directly by binding to CB1 receptors ex-
pressed in peripheral tissues involved in the regulation of
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energy metabolism, such as white adipose tissue (WAT)
(22), liver (24,25), skeletal muscle (26), and pancreas (27).
Consistent with this, the endocannabinoid system has
been reported to have a direct role in the modulation of
adipocyte metabolism. Activation of the CB1 receptor in
isolated mouse adipocytes increases the activity of li-
poprotein lipase (22), increases the number of intracellu-
lar lipid droplets, and decreases adiponectin expression
(27). CB1 receptor activation also increases hepatic fatty
acid synthesis by upregulating the lipogenic transcription
factor sterol regulatory element–binding protein-1c and its
targets acetyl-CoA carboxylase  (ACC) and fatty acid
synthase (FAS) expression (24,25), suggesting the poten-
tial involvement of the endocannabinoid system in the
pathogenesis of fatty liver. Finally, the CB1 antagonist
SR141716 increases glucose uptake in isolated soleus
muscle of ob/ob mice (26).
It is well known that the endocannabinoid/CB1 tone is
upregulated in obesity, at both the central and peripheral
levels (27–31). The important point is that CB1 activation
has multiple direct metabolic actions on tissues that are
consistent with storing more fat, and these appear to
occur independently of any transient change of energy
intake. So whereas the CB1 receptor subtype mediates
both central and peripheral actions of endocannabinoids
on energy balance, it is often unclear if endocannabinoid-
mediated changes of lipid and glucose metabolism depend
on central and/or peripheral CB1 activation (32–34). In
fact, even though chronic CB1 blockade in obese animals
and humans improves several symptoms of the metabolic
syndrome (35), it still remains to be determined whether
beneficial metabolic effects can directly result from CB1
receptor antagonism in the absence of changes in food
intake. To address these questions, we infused a CB1
antagonist centrally or peripherally into normal and DIO
rats for 1 week. This design allowed us to define the
relative contribution of peripheral CB1 receptors by spe-
cifically comparing the consequences of central versus
global CB1 antagonism. Pair-fed control groups allowed us
to determine which metabolic consequences are indepen-
dent of changes in food intake. To our knowledge, this is
the first study to systematically examine these complex,
but clinically relevant, questions. We find that chronic
global, but not isolated central, CB1 antagonism has
beneficial effects on glucose and lipid metabolism beyond
the secondary effects of decreased food intake.
RESEARCH DESIGN AND METHODS
In a first experiment, 300- to 350-g male Wistar rats, purchased from Charles
River Laboratories (L’Arbresle, France), were housed in individual cages
under controlled temperature (23°C) and illumination (12-h light/12-h dark
cycle). They were allowed ad libitum access to water and to a standard diet
(RMI; Hersteller, Essex, U.K.). In a second experiment, male Sprague-Dawley
rats were fed a 45% high-fat diet (Ssniff RM/H; Ssniff Spezialdia¨ten, Soest,
Germany) for 8 weeks before the beginning of the experiments. The animals
were handled regularly, and food intake and body weight were measured daily
during the experimental period. The animals were killed at 16 weeks of age.
Rats were tested either for euglycemic-hyperinsulinemic clamps or for mea-
surement of hormones, metabolites, and tissue-specific mRNA or protein
expression. All procedures were approved by the institutional animal care and
use committees at the University of Cincinnati, in accordance with the
National Institutes of Health guide for the care and use of laboratory animals;
the office ve´te´rinaire fe´de´ral et cantonal, Geneva; or by the animal welfare
committee at the Institute of Experimental Medicine of the Hungarian
Academy of Sciences.
Intracerebroventricular and peripheral infusions. To assess the effects of
semichronic central CB1 antagonism, SR141716 (kindly provided by Procter
and Gamble Pharmaceuticals, Mason, OH) was delivered over 6 days by
intracerebroventricular infusion, using osmotic minipumps (model 2001D,
Alzet Osmotic Pumps; Durect, Cupertino, CA). This was done under anesthe-
sia with intramuscular ketamine-xylazine (ketalar-rompun; Parke-Davis and
Bayer, Leverkusen, Switzerland) used at 50–80 and 9–13 mg/kg, respectively,
by placing a cannula tip in the right lateral cerebral ventricle, fixed on the skull
with dental cement. Following surgery, the animals received a single dose of
0.28 mg/kg buprenorphin (Buprenex; Reckitt Benckiser Healthcare, Hull,
U.K.). After 1 week of recovery, the drinking response to intracerebroventric-
ular angiotensin II injection (5 ng/l) (Novabiochem, Lau¨felfingen, Switzer-
land) was measured to confirm the correct placement of the cannula, and after
1 more week, the cannula was connected to an osmotic minipump using a
polypropylene catheter, as previously described (36). Two doses of SR141716
(3 and 5 g/rat per day) were tested. The vehicle used as a solvent was
isotonic saline with 0.3% Tween 80. For peripheral delivery of the CB1
antagonist, we performed daily intraperitoneal injection of SR141716 at a dose
of 10 mg  kg1  day1 for 6 days. This dose has been extensively used in
previous work (19,37,38). For both treatments, control rats received vehicle
(NaCl 0.9% plus 0.3% Tween 80). To differentiate between the effects of the
CB1 antagonist per se and those related to decreased food intake, groups of
vehicle-treated rats were pair fed the amount of food consumed by CB1
antagonist–treated animals. The pair-feeding regimen consisted of giving the
daily amount of food just before the onset of the dark phase. Thus, each
experiment included three groups of animals: an ad libitum–fed control group
treated intracerebroventricularly or intraperitoneally with vehicle, an intrace-
rebroventricular or intraperitoneal CB1 antagonist–treated group, and a
vehicle pair-fed control group. To exclude that the difference in the final effect
on food intake—body weight and metabolic alterations were due to the
different dosages used (5 g/rat per day i.c.v. and 10 mg  kg1  day1 i.p.)—a
dose of 5 g/rat per day was infused subcutaneously using osmotic
minipumps (model 2001D).
Preparation of mouse serum and brain samples. Chemicals were obtained
from Sigma-Aldrich (St. Louis, MO), J.T. Baker (Phillipsburg, NJ), EM Science
(Gibbstown, NJ), and Pierce (Rockford, IL). Standards and quality controls
(QCs) were prepared in whole blank or vehicle-treated homogenized mouse
brain, one individual tissue per standard or QC. Blank mouse brain was
homogenized by adding thawed tissue to a 3-ml syringe and pushing it through
an 18-gauge needle into an individual 2-ml plastic conical tube. Internal
standard in mouse serum (100 ng per 20 l) was added. Spiking standard
stocks were prepared in mouse serum. Working standards (22–22,222 ng/g)
were made by spiking an aliquot of the spiking standard stock (50 l total
volume) in the 2-ml plastic screw cap vial containing the blank homogenized
mouse brain, and 20 l internal standard in mouse serum stock solution and
samples were vortexed. For in vivo samples, whole mouse brains were
homogenized individually as above. Internal standard (100 ng per 20 l) and
50 l blank serum was added and samples were vortexed. Methanol (600 l)
was added and samples were mixed for 10 min on a multitube vortex.
Samples were centrifuged using a Hermle 2360 K centrifuge at 10,000 rpm for
10 min. The aliquot of the supernatant was transferred to a Gilson vial
containing water/methanol (70/30; vol/vol) for analysis by liquid chromatog-
raphy/mass spectrometry.
Liquid chromatography/mass spectrometry analysis. Samples were ana-
lyzed using an Applied Biosystems (Foster City, CA) PE-Sciex API 4000 mass
spectrometer with gradient reversed-phase high-performance liquid chroma-
tography/electrospray–tandem mass spectrometry with a Waters (Milford,
MA) Symmetry Shield C18 column (2.1  50 mm, 3.5 m) and selected
reaction–monitoring detection. The selected reaction–monitoring schemes
were 463 3 363 and 555 3 455 for Rimonabant and the internal standard,
respectively. Mobile phases contained acetronitrile, water, formic acid, and
N-heptafluorobutyric acid (10/90/0.2%/1 mmol/l for A and 90/10/0.2%/1 mmol/l
for B). The gradient allowed the internal standard and the analytes to be
completely resolved.
Euglycemic-hyperinsulinemic clamps. Global and tissue-specific glucose
utilization rates were measured by performing euglycemic-hyperinsulinemic
clamps associated with the labeled 2-deoxyglucose technique (39,40). In these
studies, rats were fasted overnight and intraperitoneally anesthetized with
Nembutal (50 mg/kg sodium pentobarbital; Abbott Laboratories, Chicago, IL).
Total glucose utilization and hepatic glucose production rates were measured
during euglycemic-hyperinsulinemic clamps under basal and insulin-stimu-
lated states (200 mU/ml, Actrapid HM; Novo Nordisk, Bagsvaerd, Denmark) by
infusing D-[U-14C]glucose (5 Ci/ml; Anawa Trading, Zu¨rich, Switzerland), as
previously described in detail (39,40). Immediately following euglycemic-
hyperinsulinemic clamps, the in vivo insulin-stimulated glucose utilization
index of individual tissues was determined by delivering a single bolus of
labeled 2-deoxy-D-[1-3H]glucose (30 Ci/rat; Amersham Biosciences U.K.,
Buckinghamshire, U.K.) as previously described (39,40). Rats were killed by
rapid decapitation, and tissues were rapidly removed, freeze clamped, and
stored at 80°C until use.
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Analytical procedures relative to clamp studies. The 2-deoxy-D-[1-3H]glu-
cose– and D-[U-14C]glucose–specific activities were determined in deprotein-
ized blood samples (38,39). Measurement of tissue concentration of 2-deoxy-
D-[1-3H]glucose-6-phosphate allowed calculation of the in vivo glucose
utilization index of individual tissues and was expressed in nanograms per
minute per milligram of tissue.
Quantitative RT-PCR procedure. Various tissues were sampled, freeze-
clamped, and stored at 80°C for measurement of mRNA expression of
lipoprotein lipase (LPL), acetyl-CoA carboxylase  (ACC), fatty acid
synthase (FAS), stearoyl-CoA desaturase-1 (SCD-1), carnitine palmitoyl-
transferase-1 (CPT-1), hormone-sensitive lipase, adipose triglyceride
lipase, ribosomal protein S29, and cyclophilin A by real-time quantitative
PCR (Applied Biosystems, Warrington, U.K.). For primer sequences, see
Table 1. Total RNA was extracted from frozen tissue samples using TRIzol
Reagent (Invitrogen, Carlsbad, CA). RNA integrity was assessed by per-
forming a 1% agarose gel electrophoresis in 1  Tris-borate-EDTA, and its
concentration was determined by spectrophotometry. cDNA templates for
RT-PCR were synthesized using 2 g of total RNA, random hexamers
(Microsynth, Balgach, Switzerland), deoxyribonucleotide triphosphates,
RNase inhibitor, RNAsin (Catalys; Promega, Madisson, WI), and Super-
script III (Invitrogen). Quantitative PCR was performed using SYBR Green
I DNA master mixture (Applied Biosystems) according to the standard
protocol and using 70 ng template cDNA. All primers were used at a final
concentration of 0.5 mol/l. A standard curve allowed obtaining the
relative concentration of each experimental gene. Values were normalized
by the expression of ribosomal protein S29 in WAT and by that of
cyclophilin A in the liver.
Plasma measurements. Plasma glucose was measured by the glucose
oxidase method (Glu; Roche Diagnostics, Rotkreuz, Switzerland). Plasma
nonesterified fatty acid and triglyceride levels were determined using Wako
Chemicals (Neuss, Germany) and Biome´rieux (Marcy l’Etoile, France) com-
mercial kits, respectively. Plasma corticosterone (Immunodiagnostic Systems,
Boldon, U.K.) and insulin (Linco Research, St. Charles, MO) levels were
determined using a double-antibody radioimmunoassay kit. Plasma insulin
levels were also measured by radioimmunoassay, as previously described
(41).
Triglyceride content in adipose tissue. The extraction procedure for tissue
triglycerides was adapted from methods described previously (42,43). The
triglyceride content of each sample was measured in duplicate after evapo-
ration of the organic solvent, using an enzymatic method (Randox Laborato-
ries, Crumlin, U.K.).
Statistics. Results are given as means  SE. Statistical analysis was
performed using one-way ANOVA, followed by the post hoc Tukey test. A
two-tailed P value 0.05 was considered statistically significant.
RESULTS
Chronic central CB1 antagonism suppresses food
intake and decreases body weight in a dose-depen-
dent manner in normal rats. Although it has been
reported that an acute intracerebroventricular injection
of a CB1 antagonist at 3 g/rat per day decreases food
intake (37), central CB1 blockade with that dose for 6
days had no effect on food intake or body weight in
normal rats in our paradigm (Fig. 1A–C). The higher
dose of the CB1 antagonist (5 g/rat per day for 6 days)
elicited a decrease in food intake relative to vehicle-
infused controls (Fig. 1D and E). Decreased food con-
sumption was accompanied by a loss of body weight.
Body weight loss of pair-fed vehicle-infused controls
equaled that of intracerebroventricular SR141716-
treated rats, implicating decreased food intake as the
key mechanism for this effect (Fig. 1F).
Interference of peripheral CB1 activity. To rule out
the possibility that centrally infused CB1 antagonist leaks
out of the central nervous system (CNS) into the circula-
tion and elicits a response by directly acting at peripheral
CB1, we chronically administered the CB1 antagonist
peripherally (6 days, via subcutaneous minipumps). Using
the same dose as that infused centrally (5 g/rat per day),
we were unable to detect changes in body weight or food
intake (Fig. 1G–I). We therefore conclude that the sup-
pressive effects on food intake and body weight in re-
sponse to the intracerebroventricular administration of 5
g/rat per day were entirely due to CNS-CB1.
Central and peripheral CB1 antagonism suppresses
food intake and body weight in DIO rats. After observ-
ing that a dose of 5 g/rat per day when administered
intracerebroventricularly for 6 days significantly de-
creased food intake and body weight gain in normal rats,
we assessed whether this dose would be effective in DIO
animals (Fig. 2A, experimental timeline). Chronic CNS-
CB1 blockade also suppressed food intake in DIO rats, and
TABLE 1
Primer sequences used for real-time quantitative PCR
Gene
Accession
number Forward sequence Reverse sequence
PCR
product Annealing T
ACC (rat) J03808 5’-TCC GGC TTG CAC CAT
GAT AA-3’
5’-CCC CCA AAA CGA GTA
ACA A-3’
104 54
FAS (rat) M76767 5’-AGG ATG TCA ACA AGC
CCA AG-3’
5’-ACA GAG GAG AAG
GCC ACA AA-3’
100 55
SCD-1 (rat) AF509569 5’-TGA AAG CTG AGA AGC
TGG TG-3’
5’-CAG TGTGGG CAG GAT
GAA G-3’
83 57
LPL (rat) L03294 5’-TCT CCT GAT GAT GCG
GAT TT-3’
5’-CAA CAT GCC CAT CTG
GTT TC-3’
97 54
CPT-1 (rat) L07736 5’-GGA TGG CAT GTG
GGT AAA AG-3’
5’-TAC TGA CAC AGG
CAG CCA AA-3’
203 55
Hormone-sensitive
lipase (rat) NM012859 5’-TCT ATG CGC AGG AGT
GTG TC-3’
5’-CTG GTT TCA GCC TCT
TCC TG-3’
227 60
Adipose triglyceride
lipase (rat) XM341960 5’-ACC TGT GCC TTA CCG
TTC AC-3’
5’-GGC AAG AGT GAC
ATG CAG AA-3’
186 60
Ribosomal protein
S29 (rat) X59051 5’-GCT GAA CAT GTG CCG
ACA GT-3’
5’-GGT CGC TTA GTC CAA
CTT AAT GAA G-3’
73 58
Glucose-6-
phosphate (rat)
NM013098 5’-ACC CTG GTA GCC CTG
TCT TT-3’
5’-GGG CTT TCT CTT CTG
TGT CG-3’
150 60
Cyclophilin A (rat) M19533 5’-AGC ACT GGG GAG
AAA GGA TT-3’
5’-CAT GCC TTC TTT CAC
CTT CC-3’
291 55
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the decrease was of greater magnitude on a percentage
basis than in normal rats (31 vs. 17% decrease, respec-
tively) (Fig. 2B and C). The SR141716-induced loss of body
weight was again mimicked by pair feeding. Unexpectedly,
pair feeding produced a slightly more pronounced body
weight loss than CB1 blockade in this cohort (Fig. 2D).
We subsequently compared the effects of a periph-
eral administration of CB1 antagonist (10 mg  kg1 
day1), leading to global CB1 antagonism, with the effects
of CNS-CB1 blockade in DIO rats (Fig. 2E, experimental
timeline). Peripheral infusion of the CB1 blocker
SR141716 caused a decrease in food consumption (40%
decrease, P  0.01) (Fig. 2F and G) and body weight (Fig.
2H). In contrast to what occurred following central admin-
istration, body weight reduction induced by the peripher-
ally administered CB1 antagonist was more marked than
that of pair-fed controls (Fig. 2H) (P  0.05 CB1-treated
rats vs. vehicle pair fed). This observation is consistent
with the conclusion that blockade of peripheral, but not
central, CB1 receptors leads to metabolic changes driving
body weight loss independent from food intake. No signif-
icant differences were detected in circulating glucose or
insulin levels (Table 2).
The peripheral injections have been made diluting the
CB1 antagonist in Tween 80 (0.3%), and it is known that
low concentrations of Tween may induce cellular damage.
In addition to use in the vehicle group (saline plus 0.3%
Tween 80), we have also assessed if Tween had any effect
on food intake or body weight per se. Our data indicate
that rats centrally infused with vehicle had the same food
intake and body weight as saline-infused rats (online
appendix Fig. 1 [available at http://dx.doi.org/10.2337/
db08-0161]). Thus, the metabolic actions of the CB1 antag-
onist were not altered by Tween 80.
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FIG. 1. Effects of CB1 antagonism on food intake and body weight in lean rats. A and B: Effect of a 6-day intracerebroventricular (icv) CB1
antagonist (3 g/day) infusion on food intake in lean rats. C: Effect of a 6-day intracerebroventricular CB1 antagonist (3 g/day) infusion on body
weight in lean rats. D and E: Effect of a 6-day intracerebroventricular CB1 antagonist (5 g/day) infusion on food intake in lean rats. F: Effect
of a 6-day intracerebroventricular CB1 antagonist (5 g/day) infusion on body weight in lean rats. G and H: Effect of a 6-day intraperitoneal (ip)
CB1 antagonist (5 g/day) infusion on food intake in lean rats. I: Effect of a 6-day intraperitoneal CB1 antagonist (5 g/day) infusion on body
weight in lean rats. Values are means  SE of 5–7 animals per group. *P < 0.05. A and D: , vehicle; f, CB1 antagonist; p, vehicle-pf. B, E, and
H: , vehicle; f, CB1 antagonist.
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FIG. 2. Effect of CB1 antagonism on food intake and body weight in DIO rats. A: Experimental timeline of intracerebroventricular (icv) studies.
HF, high fat; s.c., subcutaneous. B and C: Effect of a 6-day intracerebroventricular CB1 antagonist (5 g/day) infusion on food intake in DIO rats.
D: Effect of a 6-day intracerebroventricular CB1 antagonist (5 g/day) infusion on body weight in DIO rats. E: Experimental timeline of
intraperitoneal (ip) studies. F and G: Effect of a 6-day intraperitoneal CB1 antagonist (10 mg/kg) administration on food intake in DIO rats. H:
Effect of a 6-day intraperitoneal CB1 antagonist (10 mg/kg) administration on body weight in DIO rats. Values are means  SE of five to seven
animals per group. *P < 0.05; **P < 0.01; ***P < 0.001. B, F, D, and H: , vehicle; f, CB1 antagonist; p, vehicle-pf. C and G: , vehicle; f, CB1
antagonist.
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Analysis of the CB1 antagonist. Having established that
the CB1 antagonist showed a clear effect at both central
and peripheral level in reducing food intake and body
weight, we wanted to assess if this compound would reach
the brain after peripheral injection. As shown in Fig. 3 and
Table 3, mice treated with Rimonabant for 10 days at 10
mg/kg showed higher concentrations of the compound in
the brain than in the serum at the corresponding times.
This suggests an equilibrium delay between the brain and
the serum and is the likely source of the longer apparent
half-life in the brain versus the serum.
Differential effects of central versus global CB1 an-
tagonism on lipid metabolism in DIO rats. To dissect
the effects of central and peripheral CB1 antagonism on
lipid metabolism, we first determined the amount of
triglycerides in epididymal WAT (Fig. 4A and C) and
plasma (Fig. 4B and D) of DIO rats. Intracerebroventricu-
lar infusion of the CB1 antagonist did not modify triglyc-
eride levels in WAT or in plasma (Fig. 4A and B). In
contrast, WAT triglyceride content was decreased after
peripheral CB1 blockade (Fig. 4C), a decrease that was not
observed in the vehicle pair-fed control group and there-
fore cannot be secondary to CB1-induced changes in food
intake. Circulating triglyceride levels were decreased in
both the peripheral CB1 antagonist–infused animals and
the pair-fed controls (Fig. 4D), although these differences
did not reach statistical significance versus ad libitum–fed
vehicle-infused controls.
To better understand the molecular mechanisms re-
sponsible for the decreased triglyceride levels in the WAT
of DIO rats after peripheral treatment with CB1 antago-
nist, we analyzed the expression profile of key enzymes
involved in lipid metabolism. In WAT of normal rats
centrally infused with the CB1 antagonist, the expression
of genes promoting lipogenesis and triglyceride storage
(i.e., FAS, SCD-1, ACC, and LPL) was markedly reduced
(Fig. 5A), and the expression of the fat-oxidizing enzyme
CPT-1 was increased. These changes were linked to the
reduction of food intake, since the vehicle pair-fed group
had similar gene expression patterns as those observed in
the CB1 antagonist–infused group. When the same dose
of CB1 antagonist (5 g/rat per day) was given periph-
erally instead of centrally, there was no change in the
mRNA expression of any of these enzymes (online
appendix Fig. 2).
In WAT of DIO rats centrally infused with the CB1
antagonist, the only two changes observed were a
decrease in SCD-1 expression and a trend toward an
increase in the expression of CPT-1. The decrease in
SCD-1 expression was also present in the pair-fed
vehicle-infused control group, indicating that it is driven
by the hypophagic effect of SR141716 (Fig. 5B). A
similar decrease in SCD-1 and increase in CPT-1 expres-
sion were observed in DIO rats receiving peripheral
SR141716. In this case, the changes appeared to be
TABLE 3
Summary tissue–to–serum concentration ratio after dosing in
mice (C57BL/6J, male, day 10)
Tissue
Tissue-to-serum ratio (k)
3.85 0.66
Brain 8.59 3.71
Tissue
QD
dose
(mg/kg) Sample
Time
(h)
Concentration 
SD (ng/ml or
ng/g)
Pseudo
T1/2 (h)
Serum 10 Cmax 1.97 258 58.9 6.33
Cmin 25.1 20.5 9.25
Brain 10 Cmax 1.97 1010 384 9.44
Cmin 25.1 186 37.5
Data are means  SE, unless otherwise indicated. Serum and brain
concentrations of Rimonabant were determined following intraperi-
toneal dosing once daily for 10 days at 10 mg/kg. On the final day,
mice were injected with compound and killed at 2 h and 25 h
postdose and serum and brain collected and processed. The concen-
trations in the brain are 4–10 times higher than those in the serum at
the corresponding time. The ratios at the 25-h collection times are
almost two times higher than those observed at the 2-h collection.
This suggests an equilibrium delay between the brain and the serum
and is the likely source of the longer apparent half-life in the brain
versus the serum. The pseudo T1/2 values were determined from the
2- and 25-h time points and are an approximation of the compound’s
half-life.
TABLE 2
Effect of central and global CB1 blockade on plasma glucose, insulin, nonesterified fatty acid, and corticosterone levels in DIO rats
Central CB1 blockade Global CB1 blockade
Vehicle (ad
libitum fed)
CB1
antagonist
Vehical
(pair fed)
Vehicle (ad
libitum fed)
CB1
antagonist
Vehical (pair
fed)
Glucose (mmol/l) 5.35 0.77 3.78 0.12 4.11 0.24 4.07 0.62 5.32 0.59 4.53  0.38
Insulin (ng/ml) 1.67 0.35 0.58 0.12 1.04 0.17 2.25 0.36 1.38 0.23 3.45 0.73
Nonesterified fatty acids (mmol/l) 0.87 0.12 0.66 0.13 0.98 0.17 1.78 0.49 0.95 0.14 0.94 0.1
Corticosterone (ng/ml) 59.84 9.28 59.77 7.26 63.91 7.14 38.67 4.65 73.35 10.1* 75.08 9.62*
Data are means  SE of five to seven animals per group. Rats were intracerebroventricularly infused (5 g/rat per day) or peripherally
injected (10 mg  kg1  day1) with either CB1 antagonist or vehicle (controls) for 6 days. Vehicle pair-fed animals were restricted to the same
amount of food as that consumed by CB1 antagonist–infused rats. *P  0.05 vs. controls.
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independent of the hypophagia induced by the treat-
ment, since the vehicle pair-fed group had similar levels
of expression as ad libitum–fed control rats (Fig. 5C).
The expression of other fat oxidation–promoting en-
zymes, hormone-sensitive lipase, and adipose triglycer-
ide lipase was not modified by drug treatment or by pair
feeding (data not shown).
No significant difference in gene expression of the key
enzymes regulating triglyceride metabolism was observed
between the livers of treated and normal control rats (Fig.
5D). The livers of DIO rats centrally infused with the CB1
antagonist had decreased expression of SCD-1, and this
was paralleled by a similar decrease in vehicle pair-fed
animals (Fig. 5E). No modification of gene expression was
detected in the livers of DIO rats peripherally infused with
the CB1 antagonist (Fig. 5F).
Peripheral, but not central, CB1 antagonism affects
insulin sensitivity and glucose homeostasis in DIO
rats. To determine whether the CB1 antagonist–in-
duced changes in peripheral lipid metabolism may be
associated with altered insulin sensitivity, we used
euglycemic-hyperinsulinemic clamps associated with
the labeled 2-deoxyglucose technique in DIO rats with
central or peripheral CB1 blockade (Fig. 6A, experimen-
tal timeline). When infused centrally, the CB1 antago-
nist failed to elicit any change in overall insulin
sensitivity. The glucose infusion rate (GIR) (Fig. 6B),
hepatic glucose production (HGP) (Fig. 6C), and glu-
cose uptake in skeletal muscle and WAT (Fig. 7A) were
identical in vehicle and centrally SR141716-infused ani-
mals. In contrast, peripheral CB1 blockade enhanced
overall insulin sensitivity, as indicated by higher GIR
(Fig. 6D). Such an effect was likely linked to the reduced
food intake induced by the treatment, since the vehicle
pair-fed group had a similar increase in GIR (Fig. 6D).
Consistent with this result, HGP was comparably sup-
pressed in both peripherally CB1 antagonist–treated and
vehicle pair-fed rats (Fig. 6E). The suppression of HGP
in the peripherally treated rats may be explained by the
marked decrease in the expression of glucose-6-phos-
phatase in both groups (Fig. 6F). The 2-deoxyglucose
technique revealed an increase in glucose uptake by all
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skeletal muscles studied (red quadriceps, white quadri-
ceps, red gastrocnemius, white gastrocnemius, and so-
leus) in the rats peripherally treated with the CB1
antagonist (Fig. 7B). This increase in glucose utilization
in skeletal muscles was also secondary to the reduction
of food intake, as it was also observed in vehicle-infused
pair-fed controls (Fig. 7B). In contrast, glucose utiliza-
tion by adipose tissue was increased only in the periph-
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FIG. 5. Effect of CB1 antagonism on peripheral lipid metabolism. A: Effect of a 6-day intracerebroventricular (icv) CB1 antagonist (5 g/day)
infusion on epidydimal white adipose tissue mRNA expression of FAS, SCD-1, ACC, LPL, and CPT-1 in lean rats. B: Effect of a 6-day
intracerebroventricular (icv) CB1 antagonist (5 g/day) infusion on eWAT mRNA expression of FAS, SCD-1, ACC, LPL, and CPT-1 in DIO
rats. C: Effect of a 6-day intraperitoneal (ip) CB1 antagonist (10 mg/kg) administration on eWAT mRNA expression of FAS, SCD-1, ACC,
LPL, and CPT-1 in DIO rats. D: Effect of a 6-day intracerebroventricular CB1 antagonist (5 g/day) infusion on liver mRNA expression of
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erally CB1 antagonist–infused group, indicating a food-
independent effect of the treatment (Fig. 7B).
DISCUSSION
The suppression of food intake and body weight gain in-
duced by CB1 antagonists has been described in both ro-
dents and humans (6,8,10,11,35,44,45). It is also known that
CB1 antagonists improve glucose homeostasis and insulin
sensitivity, outcomes that may be secondary to decreased
body weight and/or food intake. Very recently, it was shown
that engagement of the CB1 receptor by taranabant, a CB1
inverse agonist, leads to weight loss by reducing food intake
and increasing energy expenditure and fat oxidation (10,11).
However, the precise mechanisms regulating these effects
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and the involvement of central versus peripheral CB1 recep-
tors leading to metabolic consequences for liver metabolism
and lipid storage in adipose tissue are not well understood.
To address the relevance of central versus peripheral
CB1 activation, we first compared the effects of central
CB1 blockade on food intake and body weight in normal
and DIO rodents. We observed that the CNS-CB1 antago-
nism was more effective in suppressing food intake in DIO
rats than in normal rats. This is consistent with previous
reports (17,46) demonstrating that peripheral CB1 antag-
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FIG. 6. Effect of CB1 antagonism in the regulation of insulin action
and hepatic glucose production in DIO rats. A: Schematic representa-
tion of the euglycemic-hyperinsulinemic clamps. B: Effect of a 6-day
intracerebroventricular (icv) CB1 antagonist (5 g/day) infusion on
GIR in DIO rats. C: Effect of a 6-day intracerebroventricular CB1
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(10 mg/kg) administration on GIR in DIO rats. E: Effect of a 6-day
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glucose production (HPG) in DIO rats. F: Effect of a 6-day intraperi-
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onist infusion is more effective in obese than in lean
Zucker rats. Those findings are also in agreement with the
hypothesis that the endocannabinoid/CB1 tone is upregu-
lated in obesity, both at the central and peripheral levels
(2,27–31). The mechanisms of endocannabinoid activation
in obesity are still not clear, but pathophysiological stim-
ulation of cannabinoid receptors may, in part, explain
obesity-associated metabolic changes and also offers an
explanation for the successful use of the CB1 receptor
inverse agonist/antagonist rimonabant for weight reduc-
tion and metabolic disorders of the obese (47). The
hypothesis that the endocannabinoid/CB1 tone is upregu-
lated in obesity is fully supported by our data, particularly
by the finding of a stronger effect of centrally administered
CB1 antagonist on food intake in DIO rats, as these rats
being very likely leptin insensitive have higher hypotha-
lamic levels of endocannabinoids (2) than lean rats.
An important further aim of these experiments was to
compare the effects of central and peripheral CB1 block-
ade in DIO rats. Peripheral CB1 antagonist administration
combines peripheral and central actions since the CB1
antagonist reaches the central nervous system, as previ-
ously shown by the Fos activation in different areas of the
brain (48,49) and our present findings (Fig. 3 and Table 3),
and therefore blocks not only the peripheral CB1 popula-
tion but also CNS-CB1 receptors. We were therefore able
to compare selective CNS-CB1 receptor blockade (due to
intracerebroventricular infusion) with global CB1 block-
ade in order to infer the differential contributions of CNS
and peripheral CB1 populations.
Our results indicate that both CNS- and global-CB1
blockade are effective at suppressing food intake and body
weight gain in our rodent models. That said, the reduction
of body weight in peripheral CB1 antagonist–treated rats
was significantly more robust than that of the vehicle
pair-fed group. Therefore, these data strongly imply that
peripheral CB1 antagonism has additional catabolic ac-
tions, presumably due to interaction with peripheral CB1
receptors, that result in enhanced weight loss that cannot
be entirely explained by the suppression of food intake.
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Our results also suggest that body weight and the meta-
bolic amelioration after CB1 antagonist treatment depends
on the dosage used, but the effects observed after the
central infusion of the CB1 antagonist cannot be explained
by the actions of CB1 in the periphery. Indeed, it was
shown that the anorectic effect of Rimonabant usually
disappears with time (19,38), but our experiments were
designed to elucidate which metabolic actions are inde-
pendent of food intake while the drug exerted anorectic
effects.
We next dissected the central and peripheral actions of
CB1 blockade on lipid and glucose metabolism in normal
and DIO rats. In normal animals, CNS-CB1 blockade
markedly decreased the gene expression of enzymes in-
volved in lipid synthesis and storage in the periphery,
while increasing expression of the lipid-oxidizing enzyme,
CPT-1. These results were presumably driven by the
anorexigenic effect of the CB1 antagonist, as they could be
reproduced by mimicking the decreased food intake with
a pair-feeding protocol. With regard to DIO rats, it was
previously reported that a CB1 antagonist is able to
reverse the obese phenotype through the regulation of
lipolysis and energy balance (38). However, in that study,
it was not ascertained whether those actions were second-
ary to the anorexigenic action of the compound. An
interesting finding that emerged from the present study is
the food intake–independent effect of global CB1 antago-
nism on adipocyte metabolism in DIO rats. Peripheral
infusion of the CB1 antagonist decreased the amount of
triglycerides in WAT, decreased the expression of SCD-1,
and increased the expression of CPT-1 in adipose tissue,
and the effect was greater than occurred in pair-fed
animals. Hence, hypophagia cannot account for all of the
altered lipid metabolism. Again, the hypothesis that the
endocannabinoid/CB1 tone is upregulated in obesity is
fully supported by our data, particularly by the finding of
food intake–independent metabolic effects of the CB1
antagonist on WAT triglyceride levels but not in the
skeletal muscle and liver and only on peripherally versus
centrally administered DIO rats, which is consistent with a
possibly stronger association of elevated endocannabinoid
tone with visceral WAT than with other tissues (27–29).
In the liver, on the other hand, global CB1 blockade in
DIO rats appeared to have no effect on lipid metabolism.
This is in keeping with the recent report that administra-
tion of CB1 antagonist alone did not modify the expression
of lipogenic enzymes in the liver but only prevented the
lipogenic effects induced by a CB1 agonist (24). Contrary
to our data, one study (50) has found a food intake–
independent effect on hepatic lipid metabolism when
obese Zucker rats were treated with 30 mg/kg Rimonabant
for 8 weeks, and another report (25) has suggested that
alcohol-induced steatosis was attenuated in mice treated
with 10 mg/kg Rimonabant for 3 weeks due to actions of
this compound on hepatic CB1 receptors. The discrepan-
cies between those studies and our current data might be
explained by the different methodological approaches
used, particularly the time of the treatment and the doses
used. In addition, we used rats fed a high-fat diet instead of
liquid ethanol diets or rats with genetic alterations. Col-
lectively, therefore, our results are consistent with the
conclusion that peripherally administered CB1 antagonist
acts directly on adipose tissue metabolism by increasing
lipid mobilization and decreasing lipid storage, thereby
contributing to enhanced body weight loss. These changes
might explain the more pronounced weight reduction
observed in the CB1 antagonist–infused rats compared
with pair-fed vehicle controls. In these experiments, it
must be acknowledged that some of the administered CB1
antagonist crossed the blood-brain barrier, affected CNS-
CB1 receptor populations, and reduced food intake. How-
ever, when we specifically blocked CNS-CB1 receptors
alone, these specific effects on adipocyte metabolism did
not occur. Our data therefore imply that such metabolic
actions are likely mediated by peripheral CB1 receptors.
Nonetheless, there are alternative possibilities. It may be,
for example, that the systemically administered antagonist
reaches populations of brain CB1 that are not reached by
intracerebroventricular administration. While this seems
unlikely due to the high lipid solubility of the compound, it
cannot be ruled out. Definitively answering this issue will
therefore await the availability of CB1 antagonists that can
be administered systemically and that do not penetrate the
blood-brain barrier.
Several reports indicate that the endocannabinoid sys-
tem also affects glucose homeostasis and insulin sensitiv-
ity. Clinical trials (6,8) with a CB1 receptor antagonist
have shown an improvement of insulin sensitivity after 1
year of treatment, and reports (23) on rodents indicate that
the infusion of a CB1 receptor antagonist improved glyce-
mia in DIO mice. Consistent with those reports, CB1
receptor activation was recently reported (51) to promote
glucose intolerance in rats. None of those studies, how-
ever, addressed the relative importance of central versus
peripheral CB1 receptor populations on insulin sensitivity,
nor did they determine the extent to which effects of CB1
blockade on glucose metabolism were mediated by
changes in food intake. The present data indicated that
CNS-CB1 blockade did not significantly alter overall insu-
lin sensitivity or tissue-specific glucose uptake in our
paradigm. In contrast, global CB1 blockade enhanced
overall insulin sensitivity, decreased HGP, and increased
glucose utilization in muscles and WAT. The scientific
value of such a comparison is obviously weakened by
potential influences of dose dependencies as well as the
different pharmacokinetics of central versus peripheral
administration. Nonetheless, the fact that both administra-
tion patterns led to similar suppression of food intake
suggests principal comparability. Although most of the
effects on glucose metabolism can be explained by the
anorexigenic properties of the CB1 antagonist, the effect
on WAT was independent of food intake. Contrary to our
results, there are two in vitro studies (30,52) indicating
that glucose uptake in adipocytes is increased by CB1
receptor stimulation. Although we do not have a clear
explanation for this discrepancy, it is very common that in
vivo and in vitro studies do not show similar data. Further
studies are needed to explore the precise role of cannabi-
noids on glucose homeostasis. Contrary to global CB1
blockade, CNS-CB1 blockade alone did not modify insulin
sensitivity or glucose utilization, indicating that peripheral
CB1 receptors are likely mediating the insulin-sensitizing
effects of CB1 blockade as well.
In summary and as schematized by Fig. 8, this series of
experiments demonstrates that CNS-CB1 blockade in nor-
mal rats has several effects on body weight and metabo-
lism and that many of these are secondary to a reduction
of food intake in our rodent models. These effects include
reduced efficiency of lipid storage in adipose tissue, de-
creased expression of SCD-1 in the liver and in WAT, and
decreased body weight. They occur without any alteration
in insulin sensitivity. In contrast, when the same CB1
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antagonist was administered peripherally in DIO rats,
there was an enhanced reduction of body weight and lipid
mobilization from WAT, and these effects appear to be, at
least in part, independent from food intake. These data are
in keeping with, and might even represent, one of the
mechanisms for the weight loss–independent effects on
FIG. 8. A: Schematic overview summarizing the metabolic effects of CNS-CB1 receptor blockade on peripheral tissues. Blockade of CNS-CB1 decreases
the expression of the lipid-promoting enzyme SCD-1 in liver and WAT, whereas it does not alter glucose utilization.B: Schematic overview summarizing
the metabolic effects of peripheral CB1 receptor blockade on peripheral tissues. Blockade of peripheral CB1 decreases hepatic glucose production,
promotes lipid mobilization independent of food intake, and increases glucose utilization. Combined, these parallel metabolic changes in multiple
tissues represent a synergistic shift in substrate choice and nutrient partitioning, resulting in decreased energy storage. TAG, triglycerides.
R. NOGUEIRAS AND ASSOCIATES
DIABETES, VOL. 57, NOVEMBER 2008 2989
metabolic parameters (for example, on adiponectin and
triglyceride levels) that have been suggested in several
clinical trials (5,6,8). Our results might also support the
possible use of peripherally restricted versus global CB1
antagonists in both obesity and metabolic disorders. In
view of the adverse psychiatric effects reported to occur
during the treatment of obesity and accompanying meta-
bolic disorders with CB1 antagonists, these data are of
importance because they suggest that CB1 antagonists do
not need to act centrally to be effective.
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